Eli Lilly's Q2 2026 revenue surged 47.7% to $22,974 million, but its net cash remains negative at negative $45,836 million.
According to the company's SEC filings, Eli Lilly & Co discovers, develops, and markets human pharmaceuticals globally, focusing on cardiometabolic health, oncology, immunology, and neuroscience. It sells these…